Cambridge Cog Regulatory News (COG)

29 September 2016

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

Major contract wins for CANTAB Connect

The neuroscience company Cambridge Cognition Holdings PLC (Cambridge, UK - LSE: COG), which develops and markets near patient technologies to facilitate early intervention and development of treatments for neurological disorders, today announces the signing of two major contracts using the Company's CANTAB Connect technology.

The contracts totalling US$3.67million (£2.82 million) are with US biopharmaceutical companies for late stage clinical trials and will contribute US$1.07 million (£0.82 million) to reported revenue in the second half of 2016.

The award of the contracts was expected and so the outlook for the current year remains unchanged.

Steven Powell, PhD, Chief Executive Officer, Cambridge Cognition: "Securing these contracts is further evidence of the concerted effort being made to accelerate revenue growth from our core businesses in Academic Research and Pharmaceutical Clinical Trials. Not only do we expect to secure further business from core CANTAB Connect products such as those used in the above contracts, but also products such as CANTAB Recruit and Cognition Kit which we introduced into our product portfolio earlier this year."

Notes to editors

About Cambridge Cognition

Cambridge Cognition is an international neuroscience company which develops and markets near patient cognitive assessment products to improve the understanding, diagnosis and treatment of neurological and psychiatric disorders.

For over 30 years the company's patented technology has advanced the assessment of cognition to accelerate the development of safe and effective treatments, improve patient outcomes and measure cognitive health throughout life.

Partners include the world's leading biotechnology and pharmaceutical companies, academic institutions and public-private healthcare providers.

www.cambridgecognition.com

Enquiries